Zealand Pharma — Januar 2022
-
Joseph Stringe fra Needham har en købsanbefaling og et $42 kursmål på Zealand Pharma per 20/1-22.
Joseph Stringer, Ph.D. - Needham
Joseph Stringer joined Needham & Company in 2017, where he covers biotechnology companies. Prior to Needham, Joseph worked as a research scientist at Ra Pharmaceuticals.
Needham (www.needhamco.com)
-
"Needham Thinks Zealand Pharma’s Stock is Going to Recover"
"In a report released today, Joseph Stringer from Needham maintained a Buy rating on Zealand Pharma (ZEAL – Research Report), with a price target of $42.00. The company’s shares closed last Thursday at $21.18, close to its 52-week low of $19.33."
-
tak
-
Ja, lad os så flå flow af gode nyheder der kan skabe trækket - været stllle meget længe
-
Tror ikke at markedet giver meget for anbefalingerne fra disse analytikere for tiden, desværre.
-
Det er ikke helt utænkeligt at XBI laver et pænt rebound og Zealand (og andre biotekselskaber) bliver løftet i samme omgang.
https://twitter.com/_B_I_O_T_E_C_H_/status/1486292081182232576/photo/1
(chart:XBI in historical record drawdown)
-
Hvornår var det, at de nye data skulle komme?
-
-
I lige måde Exit.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind